SECTION 1. Notwithstanding any general or special law to the contrary, there shall be a special commission to examine the prospect of establishing a system for the bulk purchasing and distribution of  pharmaceutical products with a significant public health benefit and the potential for significant health care cost savings through overall increased purchase capacity.

The commission shall consist of 11 members: 1 of whom shall be the commissioner of the department of public health, or a designee, who shall serve as chair; 1 of whom shall be the executive director of the group insurance commission, or a designee; 1 of whom shall be the chief of pharmacy of the state office of pharmacy services; 1 of whom shall be the division of medical assistance pharmacy director; 2 of whom shall be the chairs of the joint committee on health care financing; and 5 members to be appointed by the commissioner of public health, 1 of whom shall be a health care economist, 1 of whom shall be an expert in health law and policy innovation, 1  of whom shall be an academic with relevant expertise in the field, 1 of whom shall be the chief executive officer of a licensed hospital in the commonwealth and 1 of whom shall be a member of the public with experience with health care and consumer protection.

The commission shall study and evaluate all aspects related to establishing a system for the bulk purchasing and distribution of pharmaceutical products with a significant public health benefit and the potential for significant health care cost savings through overall increased purchase capacity. The commission shall hold, at a minimum, three hearings in different geographic areas of the commonwealth, and shall accept input from the public, as well as solicit expert testimony from individuals representing the following entities: health insurance companies, pharmaceutical companies, pharmacies, hospitals, municipalities, health care practitioners, community health centers, substance abuse providers, public health educational institutions and other experts as identified by the commission.

The commission shall, following the completion of the required hearings, file a report of its analysis, recommendations and any legislative or regulatory changes necessary to advance said recommendations to the clerks of the senate and house of representatives, as well as to the joint committee on ways and means, the joint committee on health care financing, the joint committee on public health, the joint committee on elder affairs and the joint committee on mental health and substance abuse. The report shall include, but not be limited to: (i) the process or processes by which the state could make bulk purchases of pharmaceutical products with a significant public health benefit and the potential for significant health care cost savings through bulk purchasing; (ii) the process or processes by which other governmental or nongovernmental entities might voluntarily participate in said collaborative in order to purchase pharmaceutical products with a significant public health benefit and the potential for significant health care cost savings; (iii) the process or processes by which the state could efficiently and economically distribute said bulk purchases; (iv) the sources of funding available to implement said bulk purchases; (v) the anticipated cost savings said bulk purchases would provide to the state and other participating governmental and nongovernmental entities; (vi) the potential to partner with the federal government and or other states in the New England region; and (vii) recommendations for how a bulk purchasing model or other leveraged purchase models could be effectively utilized by the commonwealth to reduce pharmaceutical costs for the state, other governmental and nongovernmental entities, and consumers.

The commission shall file a report not later than eight months after the enactment of this act.